# This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

> **NCT00731692** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 970 (actual)

## Conditions studied

- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** FTY720
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00731692
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07-28
- **Primary completion:** 2015-06-22
- **Final completion:** 2015-06-22
- **Target enrollment:** 970 (ACTUAL)
- **Why stopped:** The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731692, "This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00731692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*